Leerink Swann reissued their market perform rating on shares of AMAG Pharmaceuticals (NASDAQ:AMAG) in a report released on Friday morning.

Other equities analysts also recently issued reports about the company. Piper Jaffray Companies assumed coverage on AMAG Pharmaceuticals in a research report on Monday, October 23rd. They issued a neutral rating and a $18.00 price objective on the stock. ValuEngine downgraded AMAG Pharmaceuticals from a hold rating to a sell rating in a research report on Friday. B. Riley restated a hold rating and issued a $16.00 price objective on shares of AMAG Pharmaceuticals in a research report on Monday, January 29th. BidaskClub upgraded AMAG Pharmaceuticals from a strong sell rating to a sell rating in a research report on Wednesday, January 24th. Finally, Zacks Investment Research upgraded AMAG Pharmaceuticals from a sell rating to a hold rating in a research report on Wednesday, November 8th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and two have issued a buy rating to the company. The stock presently has an average rating of Hold and a consensus price target of $19.89.

AMAG Pharmaceuticals (NASDAQ AMAG) opened at $13.25 on Friday. AMAG Pharmaceuticals has a 52-week low of $11.93 and a 52-week high of $25.20. The company has a market capitalization of $463.16, a PE ratio of -2.18 and a beta of 0.79. The company has a debt-to-equity ratio of 0.94, a current ratio of 1.59 and a quick ratio of 1.48.

Several large investors have recently bought and sold shares of AMAG. State Street Corp lifted its position in shares of AMAG Pharmaceuticals by 10.6% in the second quarter. State Street Corp now owns 2,789,932 shares of the specialty pharmaceutical company’s stock worth $51,336,000 after buying an additional 267,873 shares in the last quarter. Tocqueville Asset Management L.P. purchased a new stake in shares of AMAG Pharmaceuticals in the third quarter worth about $3,958,000. Prudential Financial Inc. lifted its position in shares of AMAG Pharmaceuticals by 35.7% in the third quarter. Prudential Financial Inc. now owns 725,357 shares of the specialty pharmaceutical company’s stock worth $13,382,000 after buying an additional 190,660 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of AMAG Pharmaceuticals by 18.5% in the second quarter. Dimensional Fund Advisors LP now owns 1,215,249 shares of the specialty pharmaceutical company’s stock worth $22,361,000 after buying an additional 189,576 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. lifted its position in shares of AMAG Pharmaceuticals by 46.1% in the third quarter. Schwab Charles Investment Management Inc. now owns 424,875 shares of the specialty pharmaceutical company’s stock worth $7,839,000 after buying an additional 134,080 shares in the last quarter.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://www.watchlistnews.com/amag-pharmaceuticals-amag-market-perform-rating-reaffirmed-at-leerink-swann/1847183.html.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.